Summary

Amycretin is a novel unimolecular peptide that acts as a dual agonist of the GLP-1 and amylin receptors, developed by Novo Nordisk for obesity and weight management. Phase 1b/2a clinical trial results have been published in a peer-reviewed journal, representing early-stage evidence of weight loss. Research use only — not a licensed medicine.

Mechanism

Amycretin is a unimolecular dual agonist of the GLP-1 and amylin receptors. GLP-1 receptor activation promotes insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite. Amylin receptor activation (amylin is co-secreted with insulin from pancreatic beta cells) promotes satiety, slows gastric emptying, and reduces postprandial glucose excursions. The combination of both mechanisms in a single molecule is designed to produce enhanced weight loss and metabolic effects compared to either pathway alone.

Evidence base

Amycretin has completed Phase 1b/2a clinical trials, with results published in a peer-reviewed journal (PMID 40550231). This represents early-stage clinical evidence: a randomised controlled study, but at Phase 1b/2a with small sample sizes and short duration. Evidence is graded as limited — Phase 2b/3 confirmatory trials are needed.

Protocols

Amycretin is administered via subcutaneous injection. Phase 1b/2a trials used dose escalation designs to evaluate safety and preliminary efficacy. No established dosing protocol exists outside of clinical trial contexts.

Amycretin is an investigational compound not licensed as a medicine in the UK. It is not a controlled substance. It falls into a UK grey area: legal for research purposes but not MHRA-approved for human therapeutic use. Sale for human consumption is illegal under UK medicines regulations.

Vendor notes

Amycretin is an investigational compound in early-stage clinical development by Novo Nordisk. It is not commercially available through UK peptide vendors. No vetted vendors offer this compound. Caution is advised regarding any supplier claiming to sell amycretin.

References

  1. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. PubMed PMID: 40550231. https://pubmed.ncbi.nlm.nih.gov/40550231/
  2. Novo Nordisk amycretin clinical development programme. ClinicalTrials.gov registry.
  3. Hay DL, Chen S, Lutz TA, et al. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol Rev. 2015.